Notice of the 40th Annual General Meeting Schedule to be held on Friday, 18th July, 2025 through VC/OAVM.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has filed the notice for its 40th Annual General Meeting scheduled for Friday, 18th July 2025 at 3:30 p.m. IST, to be held via video conferencing. Key agenda items include adopting the audited FY25 financial statements, declaring a dividend of ₹18 per share (180% on ₹10 face value), and re-appointing Ashish U. Bhuta as Chairman & Managing Director for a fresh 5-year term from April 2026 to March 2031. Shareholders will also vote on appointing M/s. Nilesh Shah & Associates as Secretarial Auditors for a first 5-year term until the 2030 AGM. The filing also includes ratification of ₹2.5 lakh remuneration for Cost Auditor Kirit Mehta & Co. for FY26. The company is celebrating its 40th anniversary, listed on BSE since 1995, with flagship brands Nervijen, Powergesic, and Zix, and operations in 13 countries.
A routine AGM filing with shareholder-friendly signals: a high 180% dividend continues the company's strong payout track record, and the leadership re-appointment ensures continuity. No negative surprises — generally positive for shareholder sentiment, though the stock may see limited immediate reaction as the key items were already expected.